Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ISA 101

Drug Profile

ISA 101

Alternative Names: HPV-SLP; HPV16-SLP; Human papilloma virus type 16 E6/E7 synthetic long peptides - ISA Pharmaceuticals; ISA 101b; ISA-101; ISA-HPV; ISA-HPV-01; ISA-HPV-SLP®; SLP-HPV-01

Latest Information Update: 31 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ISA Pharmaceuticals
  • Developer Bristol-Myers Squibb; ISA Pharmaceuticals; Regeneron Pharmaceuticals; Shin Nippon Biomedical Laboratories; University of Texas M. D. Anderson Cancer Center
  • Class Cancer vaccines; Papillomavirus vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Vulvar intraepithelial neoplasia
  • New Molecular Entity No

Highest Development Phases

  • Phase III Cervical cancer
  • Phase II Oropharyngeal cancer; Solid tumours; Vulvar intraepithelial neoplasia
  • Phase I/II Anal intraepithelial neoplasia

Most Recent Events

  • 30 Nov 2018 Phase-II clinical trials in Oropharyngeal cancer (Combination therapy, Recurrent, Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT03669718)
  • 28 Sep 2018 ISA Pharmaceuticals plans a phase II trial in Oropharyngeal cancer (Combination therapy, Recurrent, Metastatic disease, Second-line therapy or greater) (NCT03669718)
  • 27 Sep 2018 ISA Pharmaceuticals plans a randomised trial for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top